Cognitive impairment (CI) is a characteristic non-motor feature of Parkinson disease (PD)
that poses a severe burden on the patients and caregivers, yet relatively little is known about …

Clinical trials in dementia with Lewy bodies: the evolving c... : Current Opinion in Neurology
Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient …

INTRODUCTION Dementia with Lewy bodies (DLB) is typically characterized by parietal,
temporal, and occipital atrophy, but less is known about the newly defined prodromal …

Dementia with Lewy bodies (DLB) is strongly associated with Alzheimer disease (AD)-type
pathology and tends to mask the core clinical features of DLB. Therefore, there may be …

Introduction Clinical parkinsonism is a core diagnostic feature for mild cognitive impairment
with Lewy bodies (MCI-LB) but can be challenging to identify. A five-item scale derived from …

This pragmatic review synthesises the current understanding of prodromal dementia with
Lewy bodies (pDLB) and prodromal Alzheimer's disease (pAD), including clinical …

Background and Objectives Retrospective studies indicate that dementia with Lewy bodies
(DLB) may be preceded by a mild cognitive impairment (MCI) prodrome. Research criteria …

Research criteria for the diagnosis of prodromal dementia with Lewy bodies (DLB) include
three clinical subtypes: mild cognitive impairment with Lewy bodies (MCI‐LB), delirium …

Numerous studies have demonstrated that dementia is associated with increased utilization
of health care services, which in turn results in increased costs of care. Dementia with Lewy …

INTRODUCTION The recent introduction of seed amplification assays (SAAs) detecting
misfolded α‐synuclein, a pathology‐specific marker for Lewy body disease (LBD), has …